You are here

  • Home
  • Archive
  • Volume 10, Issue 7
  • Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

Authors

  • Jian Ye Department of Surgery, University of Rochester Medical Center, Rochester, New York, USACenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Bradley N Mills Department of Surgery, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Shuyang S Qin Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Jesse Garrett-Larsen Department of Surgery, University of Rochester Medical Center, Rochester, New York, USACenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Joseph D Murphy Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Taylor P Uccello Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Booyeon J Han Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Tara G Vrooman Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Carl J Johnston Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USADepartment of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Edith M Lord Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Brian A Belt Department of Surgery, University of Rochester Medical Center, Rochester, New York, USACenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • David C Linehan Department of Surgery, University of Rochester Medical Center, Rochester, New York, USACenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Scott A Gerber Department of Surgery, University of Rochester Medical Center, Rochester, New York, USACenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles

Citation

Ye J, Mills BN, Qin SS, et al
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
Journal for ImmunoTherapy of Cancer 2022;10:e004784. doi: 10.1136/jitc-2022-004784
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.